Yahoo
    Tel Aviv - Delayed Quote ILA

    Can-Fite BioPharma Ltd. (CANF.TA)

    256.00 -6.90 (-2.62%)
    At close: October 30 at 1:44:53 PM GMT+2
    Loading Chart for CANF.TA
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson

    Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
    GlobeNewswire 4mo ago
    Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026

    Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
    GlobeNewswire 6d ago
    Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

    Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
    GlobeNewswire 1mo ago
    Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

    Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
    GlobeNewswire 1mo ago
    Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

    Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
    Benzinga 1mo ago
    Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

    Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
    GlobeNewswire 1mo ago
    Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

    Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
    GlobeNewswire 1mo ago
    Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer

    Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
    GlobeNewswire 2mo ago
    Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates

    Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
    GlobeNewswire 2mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: